Demodex Blepharitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for demodex blepharitis. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
9
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Demodex Blepharitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Tarsus 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating demodex blepharitis. Each bar = one year. Y-axis scaled to peak year (8 patents).

1
30
8
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xdemvy
LOTILANER
 Tarsus 9 59 — 2030-01-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12171750 Xdemvy method of use 75 2038-12-14
11690827 Xdemvy method of use 70 2038-12-14
11690826 Xdemvy method of use 70 2038-12-14
11197847 Xdemvy method of use 70 2038-12-14
10835517 Xdemvy method of use 70 2038-12-14
12364685 Xdemvy formulation 55 2038-12-14
12213964 Xdemvy formulation 55 2038-12-14
11752137 Xdemvy formulation 50 2038-12-14
8383659 Xdemvy composition of matter 18 2030-01-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8383659 Xdemvy composition of matter 18 2030-01-17
11752137 Xdemvy formulation 50 2038-12-14
12364685 Xdemvy formulation 55 2038-12-14
12213964 Xdemvy formulation 55 2038-12-14
11197847 Xdemvy method of use 70 2038-12-14
11690827 Xdemvy method of use 70 2038-12-14
11690826 Xdemvy method of use 70 2038-12-14
10835517 Xdemvy method of use 70 2038-12-14
12171750 Xdemvy method of use 75 2038-12-14

Related